Tirzepatide Dosage Guide
93/100 confidenceComplete guide to Tirzepatide dosing protocols, administration methods, and safety considerations for research purposes.
NOT Medical Advice
The dosage and calculator information provided is for educational and research purposes only. Peptides are not approved by the FDA for human use. Individual responses vary significantly. Always consult with a qualified healthcare professional before making any decisions related to peptide research or use.
Dosage Overview
Dose per Injection
2.5 mg – 15 mg
Frequency
Once per week
Route
subcutaneous
Cycle Length
16–52 weeks
Detailed Dosage Information
For weight management (Zepbound)
start at 2.5 mg weekly for 4 weeks.
Escalate to 5 mg for 4 weeks, then 7.5 mg for 4 weeks, then 10 mg.
May increase to 12.5 mg, then maximum 15 mg weekly.
For type 2 diabetes (Mounjaro)
same escalation schedule, maintenance at 5 mg, 10 mg, or 15 mg based on glycemic response.
Administration Method
Subcutaneous injection in the abdomen, thigh, or upper arm. Rotate injection sites. Pre-filled single-dose pen — no reconstitution needed. Store refrigerated before first use; may be stored at room temperature (up to 86°F) for up to 21 days. Administer on the same day each week; may change the day if the last dose was given 3+ days prior.
Research Backing
SURMOUNT 1-5 trials (weight management), SURPASS 1-5 trials (T2D). SURMOUNT-1 showed 20.9% weight loss at 15 mg dose. FDA-approved 2022 (Mounjaro), 2023 (Zepbound).
Side Effects to Monitor
Very common (>10%): nausea (up to 33%), diarrhea (up to 25%), decreased appetite, vomiting, constipation, dyspepsia, abdominal pain. Generally milder GI side effects than semaglutide, potentially due to GIP receptor co-activation. Common (1-10%): injection site reactions, fatigue, hypersensitivity reactions, GERD, hair loss, eructation.
Safety Considerations & Risks
Black box warning: thyroid C-cell tumors in rodent studies. Contraindicated in patients with personal/family history of MTC or MEN 2. Risk of pancreatitis, gallbladder events, hypoglycemia (especially with insulin/sulfonylureas). Muscle loss concerns similar to semaglutide. Not studied in patients with gastroparesis — avoid in severe GI motility disorders. Contraindicated in pregnancy.